Article
TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Nov 2020
Mayer E L, Abramson V, Jankowitz R, Falkson C, Marcom P K, Traina T, Carey L, Rimawi M, Specht J, Miller K, Stearns V, Tung N, Perou C, Richardson A L, Componeschi K, Trippa L, Tan-Wasielewski Z, Timms K, Krop I, Wolff A C, Winer E P
Abstract excerpt
BACKGROUND: Cisplatin and paclitaxel are active in triple-negative breast cancer (TNBC). Despite different mechanisms of action, effective predictive biomarkers to preferentially inform drug selection have not been identified. The homologous recombination deficiency (HRD) assay (Myriad Genetics, Inc.) detects impaired double-strand DNA break repair and may identify patients with BRCA1/2-proficient tumors that are...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.